| 1 |
Zhao X, Modur V, Carayannopoulos LN, Laterza OF. Biomarkers in pharmaceutical research. Clin Chem 2015;61:1343-53.
DOI
|
| 2 |
Miyake M, Hori S, Morizawa Y, Tatsumi Y, Toritsuka M, Ohnishi S, et al. Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. Oncotarget 2017;8:36099-114.
|
| 3 |
Roman K, Murphy SF, Done JD, McKenna KE, Schaeffer AJ, Thumbikat P. Role of PAR2 in the development of lower urinary tract dysfunction. J Urol 2016;196:588-98.
DOI
|
| 4 |
Lee T, Lim US, Kang DH, Jung HD, Kim H, Choi BH, et al. Nearnormalized gene expression profiles in bladder with detrusor overactivity in rats with bladder outlet obstruction after deobstruction. Int Neurourol J 2017;21:247-58.
DOI
|
| 5 |
Acevedo-Alvarez M, Yeh J, Alvarez-Lugo L, Lu M, Sukumar N, Hill WG, et al. Mouse urothelial genes associated with voiding behavior changes after ovariectomy and bladder lipopolysaccharide exposure. Neurourol Urodyn 2018;37:2398-405.
DOI
|
| 6 |
Ohya S, Niwa S, Kojima Y, Sasaki S, Sakuragi M, Kohri K, et al. Intermediate-conductance  -activated K+ channel, KCa3.1, as a novel therapeutic target for benign prostatic hyperplasia. J Pharmacol Exp Ther 2011;338:528-36.
DOI
|
webmaster
